JPH05271088A - Agent for improving and treating tissue disorder caused by dermatosis-immunological reaction - Google Patents
Agent for improving and treating tissue disorder caused by dermatosis-immunological reactionInfo
- Publication number
- JPH05271088A JPH05271088A JP3359875A JP35987591A JPH05271088A JP H05271088 A JPH05271088 A JP H05271088A JP 3359875 A JP3359875 A JP 3359875A JP 35987591 A JP35987591 A JP 35987591A JP H05271088 A JPH05271088 A JP H05271088A
- Authority
- JP
- Japan
- Prior art keywords
- substance
- dermatosis
- therapeutic agent
- activity
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、イボ、ニキビなどのウ
イルスまたは細菌性の皮膚疾患、日光皮膚炎などの皮膚
炎、および免疫反応による組織障害（いわゆるアレルギ
ー性疾患）の改善治療剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an agent for improving and treating viral or bacterial skin diseases such as warts and acne, dermatitis such as sunburn dermatitis, and tissue damage due to immune reaction (so-called allergic disease).
【０００２】[0002]
【従来の技術】従来より、好中球が病変部に遊走されて
くる疾患のような炎症性皮膚疾患に対しては、副腎皮質
ホルモンの外用剤や抗ヒスタミン剤あるいは抗炎症剤が
知られている。2. Description of the Related Art Conventionally, for inflammatory skin diseases such as diseases in which neutrophils migrate to lesions, external preparations of corticosteroids, antihistamines or anti-inflammatory agents are known.
【０００３】[0003]
【発明が解決しようとする課題】しかし、副腎皮質ホル
モンの外用剤、抗炎症剤、抗ヒスタミン剤は、部分的に
効果があるが、特にアレルギー疾患に関しては効果が明
確でなく、また、ウイルス性皮膚疾患や難治性皮膚疾患
に有効な治療剤は知られていない。However, although external preparations of corticosteroids, anti-inflammatory agents, and antihistamines are partially effective, the effect is not clear particularly in allergic diseases, and viral skin diseases There is no known therapeutic agent effective for treating intractable skin diseases.
【０００４】また、アレルギー疾患を根治させるには体
質改善による方法があり、その際飲食等による方法も行
われているが、飲食によるアレルギー性疾患を改善する
方法は、効果が薄いか、改善に長時間を要し十分効果の
あるものは知られていなかった。[0004] Further, there is a method of improving physical constitution to cure allergic diseases, and at that time, a method of eating and drinking is also performed. However, the method of improving allergic diseases by eating and drinking is not effective or is not effective. It was not known that it took a long time and was sufficiently effective.
【０００５】本発明は、前記課題を解決し、各種皮膚
炎、アレルギー性疾患、ウイルス・細菌性皮膚疾患、難
治性皮膚疾患に有効な改善治療剤を提供することを目的
とする。An object of the present invention is to solve the above-mentioned problems and to provide a remedy effective for various dermatitis, allergic diseases, viral / bacterial skin diseases and intractable skin diseases.
【０００６】[0006]
【課題を解決するための手段】そこで、本発明者らは、
前記目的を解決するために鋭意研究を重ねた結果、皮膚
炎・免疫反応による組織障害は、体内の活性酸素と関係
することを見出し、体内の活性酸素を除去するスーパー
オキシドジスムターゼ（ＳＯＤ）様活性を有する物質、
かつ、フェノール化合物、及び、糖蛋白質、糖化フラボ
ノイド等の糖化合物を含有する組成物が、皮膚疾患、難
治性皮膚疾患、アレルギー症状を著しく改善治療する機
能を有するとの知見を得て本発明を解決した。Therefore, the present inventors have
As a result of intensive studies to solve the above-mentioned object, it was found that the tissue damage due to dermatitis / immune reaction is related to active oxygen in the body, and superoxide dismutase (SOD) -like activity for removing active oxygen in the body is found. A substance having
Moreover, the present invention was obtained by finding that a phenol compound and a composition containing a glycoprotein such as a glycoprotein and a glycated flavonoid have a function of significantly improving and treating skin diseases, intractable skin diseases, and allergic symptoms. Settled.
【０００７】ＳＯＤ様活性とは、スーパーオキシドラジ
カルを過酸化水素に変換するスーパーオキシドジムター
ゼ活性に類似の活性（生理機能）を有するものを示し、
ＳＯＤ様活性を有する物質として、アミノ酸やペプチド
の銅（ＩＩ）錯体、マンガン錯体、脂溶性アスコルビン
酸、ポリフィリン金属錯体、ポリアミン金属錯体等の低
分子化合物が挙げられる。[0007] The SOD-like activity means that it has an activity (physiological function) similar to the superoxide dismutase activity for converting a superoxide radical into hydrogen peroxide,
Examples of the substance having SOD-like activity include low molecular compounds such as copper (II) complexes of amino acids and peptides, manganese complexes, fat-soluble ascorbic acid, porphyrin metal complexes, and polyamine metal complexes.
【０００８】また、ＳＯＤ様活性を有する物質の他に抗
酸化能を有する物質を含有することが好ましく、抗酸化
能を有する物質としては、ビタミンＣ、ビタミンＥ、尿
酸、グルタチオン、βカロチン、カラターゼ、グルタチ
オンパーオキシンダーゼ等が挙げられる。In addition to the substance having SOD-like activity, it is preferable to contain a substance having an antioxidant ability. Examples of the substance having an antioxidant ability include vitamin C, vitamin E, uric acid, glutathione, β-carotene and calatase. , Glutathione peroxinase and the like.
【０００９】フェノール化合物としては、グァイアコー
ル、フェノール、オイゲノール、フェニルエタノール等
の群より選ばれた１種またはこれらの混合物が上げられ
る。As the phenol compound, one selected from the group consisting of guaiacol, phenol, eugenol, phenylethanol and the like or a mixture thereof can be mentioned.
【００１０】糖蛋白質、糖化フラボノイド等の糖化合物
としては、アスパラチン、オリエンチン（ルテキシ
ン）、シスオリエンチン（ルトナレチン）、イソクエル
シチン、ルチン、ケルセチン等の群より選ばれた１種ま
たはこれらの混合物が挙げられる。Examples of sugar compounds such as glycoproteins and glycated flavonoids include one selected from the group consisting of aspalathin, orientin (lutexin), cis-orientin (rutonaretin), isoquercitin, rutin, quercetin and the like, or a mixture thereof. Be done.
【００１１】また、本発明は、リン、鉄、カルシウム、
ナトリウム、カリウム、マグネシウム、銅、亜鉛、マン
ガン、セレン等の１種またはこれらの混合物であるミネ
ラルを混合すればより効果が優れる。The present invention also provides phosphorus, iron, calcium,
The effect is more excellent when one or more of sodium, potassium, magnesium, copper, zinc, manganese, selenium and the like or a mixture of these minerals is mixed.
【００１２】本発明の構成物質はいずれも無毒性のもの
で薬理基準にも合致したものである。All the constituents of the present invention are non-toxic and comply with pharmacological standards.
【００１３】本発明は、ＳＯＤ様活性を有する物質、糖
化フラボノイド及びフェノール化合物、また必要に応じ
て添加される抗酸化能を有する物質やミネラルを含有す
ることによって初めて優れた効果を示すのであり、その
構成は、ＳＯＤ様活性の力価が１０，０００〜１００，
０００単位／ｌ、糖化合物０．１〜１０ｍｇ／ｌ、蛋白
性物質０．５〜１０ｍｇ／ｍｌ、及びフェノール化合物
を０．１〜５ｍｇ／ｌ、またミネラルを添加するとき
は、１０〜５００ｍｇ／ｌ含有することが必要である。The present invention exhibits an excellent effect for the first time by containing a substance having an SOD-like activity, a glycated flavonoid and a phenol compound, and a substance or mineral having an antioxidant ability which is added as necessary. The composition has a titer of SOD-like activity of 10,000-100,
000 units / l, sugar compound 0.1 to 10 mg / l, proteinaceous substance 0.5 to 10 mg / ml, phenol compound 0.1 to 5 mg / l, and when minerals are added, 10 to 500 mg / l 1 must be included.
【００１４】本発明に用いる、ＳＯＤ様活性を有する物
質、糖成分、フェノール化合物は、混合してそのまま溶
液、粉末顆粒、錠剤、乳剤、ゼリー状など任意の形態で
単独投与、または、他の飲食物に混合して飲食すること
もできる。The substance having SOD-like activity, sugar component, and phenol compound used in the present invention are mixed and directly administered in any form such as solution, powder granule, tablet, emulsion, jelly, or other food or drink. It can also be mixed with food and eaten.
【００１５】投与量は、対象となる疾患の種類、程度に
より異なるが、２〜４０ｍｇ／ｋｇ体重／日の範囲で用
いるのが好ましく、飲料として常用する場合には、０．
１〜３．０％溶液を１００ｍｌ〜１５００ｍｌ／日飲食
するのが好ましい。Although the dose varies depending on the kind and degree of the target disease, it is preferably used in the range of 2 to 40 mg / kg body weight / day, and when used as a beverage, it is preferably 0.
It is preferable to eat and drink 100 ml to 1500 ml / day of a 1 to 3.0% solution.
【００１６】[0016]
【作用】皮膚疾患はその原因が複雑なものが多く、本発
明の詳細な作用は不明な点が多いが、炎症性疾患の場合
には、ＳＯＤ様活性を有する物質がスーパーオキシドラ
ジカル、ヒドロキシラジカルなどで体内の活性酸素を除
去し、糖化合物が抗酸化作用を、またフェノール化合物
が殺菌作用を有してこれらが複合的に結合して作用する
ものと考えられる。[Effects] Many skin diseases have complicated causes, and the detailed effects of the present invention are unknown, but in the case of inflammatory diseases, substances having SOD-like activity are superoxide radicals and hydroxy radicals. It is considered that the active oxygen in the body is removed by, for example, the sugar compound has an antioxidant action, and the phenol compound has a bactericidal action, and these compounds are combined to act.
【００１７】[0017]
【効果】本発明は、ヒトを含む哺乳動物の皮膚炎、イ
ボ、ニキビなどのウイルスまたは細菌性の皮膚疾患、日
光皮膚炎などの皮膚炎、およびアトピー性皮膚、アレル
ギー性疾患、難治性皮膚疾患を副作用なく、迅速に改善
することができ、また、副作用がないため飲食等により
服用し、アレルギー性疾患を根治することができる。ま
た、本発明は従来の薬剤と併用すればさらに良い効果を
得ることができる。[Effects] The present invention is directed to dermatitis of mammals including humans, viral or bacterial skin diseases such as warts and acne, dermatitis such as sunburn dermatitis, and atopic skin, allergic diseases, and intractable skin diseases. Can be rapidly improved without side effects, and since there are no side effects, it can be taken by eating or drinking to cure allergic diseases. In addition, the present invention can obtain a better effect when used in combination with a conventional drug.
【００１８】[0018]
製造例 糖化合物として糖化フラボノイド０．１〜１０ｍｇ／
ｌ、蛋白質０．５〜１０ｍｇ／ｍｌ、フェノール化合物
０．１〜５ｍｇ／ｌを溶液状のまま混合し、ＳＯＤ様活
性、抗酸化能として力価２０，０００単位／ｇ以上とな
るように調製した。得られた組成物に蒸留水を添加し、
組成物が０．１ｍｇ／ｍｌ（０．０１％）以上含有する
溶液を得た。Production Example Saccharified flavonoid as sugar compound 0.1 to 10 mg /
1, protein 0.5 to 10 mg / ml, phenol compound 0.1 to 5 mg / l were mixed as a solution, and prepared so as to have a SOD-like activity and an antioxidant potency of 20,000 units / g or more. did. Distilled water was added to the obtained composition,
A solution containing 0.1 mg / ml (0.01%) or more of the composition was obtained.
【００１９】実施例 製造例で得た溶液を表１に示す各種皮膚炎およびアレル
ギー性疾患の患者に１日３００から５００ｍｌを２週間
飲ませ、疾患の改善を調べ、その結果を表１に示す。Example The solutions obtained in the production examples are given in Table 1 to patients with various dermatitis and allergic diseases by ingesting 300 to 500 ml per day for 2 weeks, the improvement of the diseases was examined, and the results are shown in Table 1. ..
【表１】 [Table 1]
───────────────────────────────────────────────────── フロントページの続き (72)発明者 中野 昌俊 愛知県知立市新林町茶野36−16 (72)発明者 進藤 泰子 長野県松本市大村1076−１ ─────────────────────────────────────────────────── ─── Continuation of front page (72) Inventor Masatoshi Nakano 36-16 Chano, Shinbayashi-cho, Chiryu-shi, Aichi (72) Inventor Yasuko Shindo 1076-1 Omura, Matsumoto-shi, Nagano
Claims (3)
Ｄ）様活性を有する物質、フェノール化合物、及び、糖
蛋白質、糖化フラボノイド等の糖化合物を含有してなる
皮膚疾患・免疫反応による組織障害改善治療剤。1. Superoxide dismutase (SO
D) A therapeutic agent for improving tissue disorders caused by skin diseases / immune reactions, which comprises a substance having a similar activity, a phenol compound, and a sugar compound such as glycoprotein and glycated flavonoid.
ェノール、オイゲノール、フェニルエタノール等の群よ
り選ばれた１種またはこれらの混合物であることを特徴
とする請求項１記載の皮膚疾患・免疫反応による組織障
害改善治療剤。2. Amelioration of a tissue disorder caused by a skin disease / immune reaction according to claim 1, wherein the phenol compound is one kind selected from the group of guaiacol, phenol, eugenol, phenylethanol and the like or a mixture thereof. Therapeutic agent.
物がアスパラチン、オリエンチン（ルテキシン）、シス
オリエンチン（ルトナレチン）、イソクエルシチン、ル
チン、ケルセチン等の群より選ばれた１種またはこれら
の混合物であることを特徴とする請求項１記載の皮膚疾
患・免疫反応による組織障害改善治療剤。3. A sugar compound such as a glycoprotein or a glycated flavonoid is one selected from the group consisting of aspalathin, orientin (lutexin), cis-orientin (lutonaretin), isoquercitin, rutin, quercetin or a mixture thereof. The therapeutic agent for improving tissue damage due to skin disease / immune reaction according to claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3359875A JPH05271088A (en) | 1991-12-27 | 1991-12-27 | Agent for improving and treating tissue disorder caused by dermatosis-immunological reaction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3359875A JPH05271088A (en) | 1991-12-27 | 1991-12-27 | Agent for improving and treating tissue disorder caused by dermatosis-immunological reaction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH05271088A true JPH05271088A (en) | 1993-10-19 |
Family
ID=18466753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3359875A Pending JPH05271088A (en) | 1991-12-27 | 1991-12-27 | Agent for improving and treating tissue disorder caused by dermatosis-immunological reaction |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH05271088A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07118151A (en) * | 1993-10-21 | 1995-05-09 | Kureha Chem Ind Co Ltd | Therapeutic agent for atopic dermatitis |
| WO1997004791A1 (en) * | 1995-07-31 | 1997-02-13 | Mitsui Norin Co., Ltd. | Antiviral agent and process for preparing the same |
| EP0868914A1 (en) * | 1997-04-01 | 1998-10-07 | Panacea Biotec Limited | Pharmaceutical composition for the control and treatment of anorectal and colonic diseases |
| WO1999044578A1 (en) * | 1998-03-05 | 1999-09-10 | Merck Patent Gmbh | Formulations with an anti-viral effect |
| WO2004014413A1 (en) * | 2002-07-31 | 2004-02-19 | Procyte Corporation | Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto |
| WO2006098603A3 (en) * | 2005-03-18 | 2006-11-30 | Unigen Inc | Composition comprising isoorientin for suppressing histamine |
| EP1684737A4 (en) * | 2003-11-07 | 2009-11-11 | Oaky Natural Co Ltd | Pharmaceutical composition containing guaiacol derivatives and syringol derivatives extracted from natural plant vinegar |
| US8247007B2 (en) | 2006-10-12 | 2012-08-21 | Unigen, Inc. | Composition for treating atopic dermatitis comprising extracts of bamboo and Scutellaria |
| US9061039B2 (en) | 2002-03-01 | 2015-06-23 | Unigen, Inc. | Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors |
| US9168242B2 (en) | 2002-03-22 | 2015-10-27 | Unigen, Inc. | Isolation of a dual COX-2 and 5-lipdxygenase inhibitor from Acacia |
| US9370544B2 (en) | 2002-04-30 | 2016-06-21 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
| US9622964B2 (en) | 2003-04-04 | 2017-04-18 | Unigen, Inc. | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
-
1991
- 1991-12-27 JP JP3359875A patent/JPH05271088A/en active Pending
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07118151A (en) * | 1993-10-21 | 1995-05-09 | Kureha Chem Ind Co Ltd | Therapeutic agent for atopic dermatitis |
| WO1997004791A1 (en) * | 1995-07-31 | 1997-02-13 | Mitsui Norin Co., Ltd. | Antiviral agent and process for preparing the same |
| US5929047A (en) * | 1995-07-31 | 1999-07-27 | Mitsui Norin Co., Ltd. | Anti-viral agent prepared by basic and acidic extraction of mangraves |
| EP0868914A1 (en) * | 1997-04-01 | 1998-10-07 | Panacea Biotec Limited | Pharmaceutical composition for the control and treatment of anorectal and colonic diseases |
| WO1999044578A1 (en) * | 1998-03-05 | 1999-09-10 | Merck Patent Gmbh | Formulations with an anti-viral effect |
| US9061039B2 (en) | 2002-03-01 | 2015-06-23 | Unigen, Inc. | Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors |
| US9168242B2 (en) | 2002-03-22 | 2015-10-27 | Unigen, Inc. | Isolation of a dual COX-2 and 5-lipdxygenase inhibitor from Acacia |
| US9370544B2 (en) | 2002-04-30 | 2016-06-21 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
| US9655940B2 (en) | 2002-04-30 | 2017-05-23 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
| US9849152B2 (en) | 2002-04-30 | 2017-12-26 | Unigen, Inc. | Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent |
| WO2004014413A1 (en) * | 2002-07-31 | 2004-02-19 | Procyte Corporation | Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto |
| US9622964B2 (en) | 2003-04-04 | 2017-04-18 | Unigen, Inc. | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
| EP1684737A4 (en) * | 2003-11-07 | 2009-11-11 | Oaky Natural Co Ltd | Pharmaceutical composition containing guaiacol derivatives and syringol derivatives extracted from natural plant vinegar |
| JP2008533131A (en) * | 2005-03-18 | 2008-08-21 | ユニジェン インク． | Histamine-suppressing composition containing isoorientin |
| WO2006098603A3 (en) * | 2005-03-18 | 2006-11-30 | Unigen Inc | Composition comprising isoorientin for suppressing histamine |
| US8247007B2 (en) | 2006-10-12 | 2012-08-21 | Unigen, Inc. | Composition for treating atopic dermatitis comprising extracts of bamboo and Scutellaria |
| US8771761B2 (en) | 2006-10-12 | 2014-07-08 | Unigen, Inc. | Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria |
| US9623068B2 (en) | 2006-10-12 | 2017-04-18 | Unigen, Inc. | Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5576299A (en) | Formulated medicine for treatment and prevention of opportunistic infectious diseases complicated by infection with lentivirus | |
| KR20090088894A (en) | Extract powder of indigo-containing plant, method for production thereof, and use thereof | |
| JP2004506657A (en) | Bioavailable compositions of natural and synthetic HCA | |
| JPH05271088A (en) | Agent for improving and treating tissue disorder caused by dermatosis-immunological reaction | |
| US20120082720A1 (en) | Compositions For Treating Chronic Viral Infections | |
| GB2374008A (en) | Compositions including copper and their uses | |
| JP2006225270A (en) | Tripeptide having sex hormone modification action, extract containing the same, eicosapentaenoic acid-bonded tripeptide, food preparation, cosmetic preparation and endometriosis treating agent containing the same | |
| JP3610358B2 (en) | Antioxidant | |
| JPH05271090A (en) | Agent for eliminating/removing active oxygen | |
| JPH06199695A (en) | Agent for amelioration and treatment of diabetes | |
| US8647635B2 (en) | Compositions comprising red microalgae polysaccharides and metals | |
| US20090082269A1 (en) | Agent for ameliorating heavy metal-induced disorders, and medicinal composition, food and cosmetic containing the same | |
| JPH06199694A (en) | Agent for stabilizing blood pressure | |
| JPH0840923A (en) | Nutrient-supplying agent | |
| KR20050029582A (en) | Antioxidation composition comprising arginine-conjugated linoleic acid | |
| EP1679079A1 (en) | Plant seed extract composition and process for producing the same | |
| JPH06199693A (en) | Agent for amelioration and treatment of ischemic disease | |
| JP2005263782A (en) | Antioxidative peptide derived from royal jelly | |
| US5830914A (en) | Apoptosis-controlling agent | |
| JP2006160625A (en) | Water-soluble extract derived from bee larva having protease inhibitory action, method for producing the same, and product containing the same | |
| JPH06199692A (en) | Agent for amelioration and treatment of cataract | |
| US20120231096A1 (en) | Composition and method of treating lipid encapsulated virus infections | |
| JP2003012538A (en) | Antioxidant agent | |
| JP2003335665A (en) | Composition for regulating in vivo vitamin c level | |
| JPH05246842A (en) | Agent for ameliorating and curing anemia |